CN Patent

CN105407875A — 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法

Assigned to Sanofi Aventis France · Expires 2016-03-16 · 10y expired

What this patent protects

本发明涉及用于治疗结核病的口服药物固定剂量组合物及其制备方法，所述口服药物组合物包含：a)包含异烟肼和至少一种颗粒内赋形剂的颗粒；b)包含利福喷汀和至少一种颗粒内赋形剂的颗粒；及c)至少一种颗粒外赋形剂。

USPTO Abstract

本发明涉及用于治疗结核病的口服药物固定剂量组合物及其制备方法，所述口服药物组合物包含：a)包含异烟肼和至少一种颗粒内赋形剂的颗粒；b)包含利福喷汀和至少一种颗粒内赋形剂的颗粒；及c)至少一种颗粒外赋形剂。

Drugs covered by this patent

doxepin-hydrochloride (DOXEPIN HYDROCHLORIDE)

Patent Metadata

Patent number: CN105407875A
Jurisdiction: CN
Classification: —
Expires: 2016-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.